Pub Date : 2024-10-22DOI: 10.1053/j.gastro.2024.06.041
Avinash Tiwari
No Abstract
无摘要
{"title":"CHRONICLE trial: how cool is cold snaring for endoscopic mucosal resection?","authors":"Avinash Tiwari","doi":"10.1053/j.gastro.2024.06.041","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.06.041","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"21 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142486447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-22DOI: 10.1053/j.gastro.2024.07.048
Koki Nakajima, Hiroaki Saito, Yoshitaka Nishikawa
No Abstract
无摘要
{"title":"Detailed information on Cold Snare Resection in Large Colorectal Polyps","authors":"Koki Nakajima, Hiroaki Saito, Yoshitaka Nishikawa","doi":"10.1053/j.gastro.2024.07.048","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.07.048","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"17 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1053/j.gastro.2024.09.037
James Cheng-Chung Wei, Poi Kuo, Qi Mei
No Abstract
无摘要
{"title":"Methodology of Study on GLP-1 Receptor Agonists and Hepatocellular Carcinoma Risk","authors":"James Cheng-Chung Wei, Poi Kuo, Qi Mei","doi":"10.1053/j.gastro.2024.09.037","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.09.037","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"17 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1053/j.gastro.2024.09.039
James Cheng-Chung Wei, Ching-Nung Wu, Wei-Chun Cheng
No Abstract
无摘要
{"title":"Comments on “Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes”","authors":"James Cheng-Chung Wei, Ching-Nung Wu, Wei-Chun Cheng","doi":"10.1053/j.gastro.2024.09.039","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.09.039","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"23 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1053/j.gastro.2024.09.035
Jean P. Molleston, Nathan P. Goodrich, Wen Ye, Daniel H. Leung, Ronald J. Sokol, Benjamin L. Shneider
No Abstract
无摘要
{"title":"Prospective Analysis of Liver Stiffness Measurement by Vibration Controlled Transient Elastography as a Predictor of Outcomes in Biliary Atresia","authors":"Jean P. Molleston, Nathan P. Goodrich, Wen Ye, Daniel H. Leung, Ronald J. Sokol, Benjamin L. Shneider","doi":"10.1053/j.gastro.2024.09.035","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.09.035","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"20 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1053/j.gastro.2024.07.046
Ashwin N. Ananthakrishnan, M. Hassan Murad, Frank I. Scott, Manasi Agrawal, John P. Haydek, Berkeley N. Limketkai, Edward V. Loftus, Siddharth Singh
Background & Aims
We performed an updated systematic review and network meta-analysis to inform the 2024 American Gastroenterological Association (AGA) Clinical Guidelines on the management of moderate-to-severe ulcerative colitis (UC).
Methods
We searched multiple electronic databases through November 21, 2023, to identify randomized controlled trials in adults with moderate-to-severe UC, comparing different advanced therapies (tumor necrosis factor antagonists, vedolizumab, sphingosine-1-phosphate receptor modulators, interleukin 12/23 or selective interleukin 23 antagonists, and Janus kinase [JAK] inhibitors) against placebo or another active comparator. Our primary outcomes were induction and maintenance of clinical remission, and our secondary outcome was endoscopic improvement. We performed a network meta-analysis using a frequentist approach and applied Grading of Recommendations, Assessment, Development and Evaluation (GRADE) to appraise certainty of evidence.
Results
After excluding JAK inhibitors as potential first-line treatment (in accordance with the United States Food and Drug Administration), low-certainty evidence supports clinically important benefit with infliximab, ozanimod, risankizumab, and guselkumab over adalimumab and mirikizumab for achieving remission with induction therapy in biologically naïve patients with moderate-to-severe UC, with risankizumab and ozanimod being ranked the highest for induction of clinical remission. With the inclusion of JAK inhibitors as first-line therapy, upadacitinib was more efficacious compared with all other medications except ozanimod and risankizumab, with low- to moderate-certainty evidence. In patients with prior biologic exposure, upadacitinib, tofacitinib, and ustekinumab were ranked highest for achieving remission.
Conclusions
Using Grading of Recommendations, Assessment, Development and Evaluation to appraise quality of evidence, this updated network meta-analysis will be used to inform comparative efficacy and positioning of advanced therapies for the treatment of biologic-naïve and biologic-exposed patients with moderate-to-severe UC.
{"title":"Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis","authors":"Ashwin N. Ananthakrishnan, M. Hassan Murad, Frank I. Scott, Manasi Agrawal, John P. Haydek, Berkeley N. Limketkai, Edward V. Loftus, Siddharth Singh","doi":"10.1053/j.gastro.2024.07.046","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.07.046","url":null,"abstract":"<h3>Background & Aims</h3>We performed an updated systematic review and network meta-analysis to inform the 2024 American Gastroenterological Association (AGA) Clinical Guidelines on the management of moderate-to-severe ulcerative colitis (UC).<h3>Methods</h3>We searched multiple electronic databases through November 21, 2023, to identify randomized controlled trials in adults with moderate-to-severe UC, comparing different advanced therapies (tumor necrosis factor antagonists, vedolizumab, sphingosine-1-phosphate receptor modulators, interleukin 12/23 or selective interleukin 23 antagonists, and Janus kinase [JAK] inhibitors) against placebo or another active comparator. Our primary outcomes were induction and maintenance of clinical remission, and our secondary outcome was endoscopic improvement. We performed a network meta-analysis using a frequentist approach and applied Grading of Recommendations, Assessment, Development and Evaluation (GRADE) to appraise certainty of evidence.<h3>Results</h3>After excluding JAK inhibitors as potential first-line treatment (in accordance with the United States Food and Drug Administration), low-certainty evidence supports clinically important benefit with infliximab, ozanimod, risankizumab, and guselkumab over adalimumab and mirikizumab for achieving remission with induction therapy in biologically naïve patients with moderate-to-severe UC, with risankizumab and ozanimod being ranked the highest for induction of clinical remission. With the inclusion of JAK inhibitors as first-line therapy, upadacitinib was more efficacious compared with all other medications except ozanimod and risankizumab, with low- to moderate-certainty evidence. In patients with prior biologic exposure, upadacitinib, tofacitinib, and ustekinumab were ranked highest for achieving remission.<h3>Conclusions</h3>Using Grading of Recommendations, Assessment, Development and Evaluation to appraise quality of evidence, this updated network meta-analysis will be used to inform comparative efficacy and positioning of advanced therapies for the treatment of biologic-naïve and biologic-exposed patients with moderate-to-severe UC.","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"23 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：